Diabetes Control and Complications Trial (DCCT): results of feasibility study
2 Relationship between GLP-1 and obesity The mechanism for the decrease in GLP-1 secretion is incompletely understood in obese people
Step 3: Apply and Complete Screening When you find a trial that you think is right for you, youll need to reach out to the sponsor listed on the trial
doi: 10.1155/2011/279530 23 JallehRJMaratheCSRaynerCKJonesKLUmapathysivamMMWuTet al
Weve really been working towards educating providers, first of all, about recognizing that and learning how to talk to and work with patients to really destigmatize the whole weight piece, Reid says
Injection burden 1-2 injections per day on overlap days Best for Metabolic + mitochondrial pairing Cycle driver Retatrutide titration sets the pace Retatrutide Loading 1 2 4 6 9 mg (every 4 weeks) Frequency Once weekly Maintenance 9 mg or 12 mg weekly Route SubQ MOTS-c (intermittent - most common) Loading Start Week 5: 5 mg, 2x weekly Frequency 2-3x weekly Maintenance 5-10 mg, 2-3x weekly Route SubQ MOTS-c (low-dose daily - alternative) Loading Start Week 5: 200 mcg/day, +200 mcg every 2 weeks Frequency Daily Maintenance Up to 1 mg daily Route SubQ Weekly Schedule Example - Intermittent MOTS-c (Weeks 5-16) Monday Retatrutide 2 mg (morning) + MOTS-c 5 mg (pre-training) Tuesday Rest day Wednesday MOTS-c 5 mg (pre-training) Thursday Rest day Friday MOTS-c 5 mg (pre-training) Saturday Rest day Sunday Rest day Community protocols use different injection sites and separate syringes when both compounds are dosed the same day
